<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-14163R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Gastroenterology and Hepatology/Gastrointestinal Cancers</subject><subject>Oncology/Gastrointestinal Cancers</subject><subject>Pathology/Pathophysiology</subject></subj-group></article-categories><title-group><article-title><italic>Fas/CD95</italic> Deficiency in <italic>Apc<sup>Min/&#x0002b;</sup></italic> Mice Increases Intestinal Tumor Burden</article-title><alt-title alt-title-type="running-head">Fas and ApcMin Mice</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guillen-Ahlers</surname><given-names>Hector</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Suckow</surname><given-names>Mark A.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castellino</surname><given-names>Francis J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ploplis</surname><given-names>Victoria A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Freimann Life Science Center, University of Notre Dame, Notre Dame, Indiana, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Tan</surname><given-names>Patrick</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Duke-NUS Graduate Medical School, Singapore</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>vploplis@nd.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: HGA FC VAP. Performed the experiments: HGA. Analyzed the data: HGA MAS FC VAP. Wrote the paper: HGA FC VAP.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>5</day><month>2</month><year>2010</year></pub-date><volume>5</volume><issue>2</issue><elocation-id>e9070</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Guillen-Ahlers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Fas, a member of the tumor necrosis family, is responsible for initiating the apoptotic pathway when bound to its ligand, Fas-L. Defects in the Fas-mediated apoptotic pathway have been reported in colorectal cancer.</p></sec><sec><title>Methodology/Principal Findings</title><p>In the present study, a variant of the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse, a model for the human condition, Familial Adenomatous Polyposis (FAP), was generated with an additional deficiency of Fas <italic>(Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup>)</italic> by cross-breeding <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice with Fas deficient (<italic>Fas<sup>lpr</sup></italic>) mice. One of the main limitations of the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model is that it only develops benign polyps. However, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice presented with a dramatic increase in tumor burden relative to <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice and invasive lesions at advanced ages. Proliferation and apoptosis markers revealed an increase in cellular proliferation, but negligible changes in apoptosis, while p53 increased at early ages. Fas-L was lower in <italic>Apc<sup>Min/&#x0002b;</sup></italic>/<italic>Fas<sup>lpr</sup></italic> mice relative to <italic>Apc<sup>Min/&#x0002b;</sup></italic> cohorts, which resulted in enhanced inflammation.</p></sec><sec><title>Conclusions/Significance</title><p>This study demonstrated that imposition of a Fas deletion in an <italic>Apc<sup>Min/&#x0002b;</sup></italic> background results in a more aggressive phenotype of the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model, with more rapid development of invasive intestinal tumors and a decrease in Fas-L levels.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Apoptosis is a regulated process that eliminates individual cells that are damaged or infected. There are several signals capable of triggering apoptosis, of which the activation of Fas/CD95/Apo-1 receptor (Fas) by Fas ligand (Fas-L) is the most studied <xref ref-type="bibr" rid="pone.0009070-Ashkenazi1">&#x0005b;1&#x0005d;</xref>. Most information about the Fas pathway is based on the immune system, where Fas is highly expressed in activated T and B cells, thymocytes, and lung and liver cells <xref ref-type="bibr" rid="pone.0009070-Lee1">&#x0005b;2&#x0005d;</xref>. Cloning of the Fas receptor (<italic>lpr</italic>) <xref ref-type="bibr" rid="pone.0009070-Itoh1">&#x0005b;3&#x0005d;</xref> and the Fas-L (<italic>gld</italic>) <xref ref-type="bibr" rid="pone.0009070-Suda1">&#x0005b;4&#x0005d;</xref> genes led to studies involving their potential roles in the activation of the apoptotic pathway by death receptors. From these studies, a potential mechanism evolved in which interaction of Fas-L with Fas results in a conformational change of the receptor resulting in the assembly of the death-inducing signaling complex, which is able to recruit and cleave procaspase-8 (reviewed in <xref ref-type="bibr" rid="pone.0009070-Danial1">&#x0005b;5&#x0005d;</xref>).</p><p>During colon cancer, regulation of the Fas system facilitates tumor development. Some studies have shown that resistance of colon carcinoma cells to apoptosis can be attributed to the elevated expression of Fas-associated phosphatase-1 <xref ref-type="bibr" rid="pone.0009070-Yao1">&#x0005b;6&#x0005d;</xref>, which inhibits Fas signaling by binding to the cytoplasmic tail of Fas. Another factor that may contribute to apoptosis resistance is incomplete Fas surface expression, with appropriate Fas mRNA levels but deficient posttranslational processing, attenuating its cell surface expression and remaining inactivated <xref ref-type="bibr" rid="pone.0009070-Mahidhara1">&#x0005b;7&#x0005d;</xref>. Amplification of a decoy receptor for Fas-L in lung and colon cancer has also been reported <xref ref-type="bibr" rid="pone.0009070-Pitti1">&#x0005b;8&#x0005d;</xref>. A number of investigations have proposed a &#x0201c;Fas counterattack&#x0201d;, which is thought to be an anti-host tumor-derived response <xref ref-type="bibr" rid="pone.0009070-OConnell1">&#x0005b;9&#x0005d;</xref>, where lymphocyte proliferation is compromised by tumor cells expressing Fas-L. This induces apoptosis in the lymphocytes, sparing tumor cells due to another mechanism, i.e., low Fas surface expression <xref ref-type="bibr" rid="pone.0009070-OConnell2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Vaux1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Yagita1">&#x0005b;12&#x0005d;</xref>. This notion however, remains controversial, and has been refuted by some investigators <xref ref-type="bibr" rid="pone.0009070-Restifo1">&#x0005b;13&#x0005d;</xref> and contradicted by other <italic>in vivo</italic> studies <xref ref-type="bibr" rid="pone.0009070-Arai1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Chappell1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Kang1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Fingleton1">&#x0005b;17&#x0005d;</xref>.</p><p>The adenomatous polyposis coli multiple intestinal neoplasia (<italic>Apc<sup>Min/&#x0002b;</sup></italic>) mouse model presents phenotypes reminiscent of Familial Adenomatous Polyposis (FAP) in humans <xref ref-type="bibr" rid="pone.0009070-Su1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Moser1">&#x0005b;19&#x0005d;</xref>. Patients with FAP develop multiple adenomas in the large intestine, which lead to the development of malignant adenocarcinomas. The relevance of the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model is that most colorectal cancers also show alterations in expression of the <italic>Apc</italic> gene <xref ref-type="bibr" rid="pone.0009070-Kinzler1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Matloff1">&#x0005b;21&#x0005d;</xref>. Apc is a gatekeeper that regulates the levels of &#x003b2;-catenin <xref ref-type="bibr" rid="pone.0009070-Reya1">&#x0005b;22&#x0005d;</xref>, a transcription factor that has <italic>Matrix metalloproteinase-7</italic><xref ref-type="bibr" rid="pone.0009070-Castellone1">&#x0005b;23&#x0005d;</xref> among its target genes. In the current study, <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice were crossed with Fas deficient (<italic>Fas<sup>lpr</sup></italic>) mice to generate <italic>Apc<sup>Min/&#x0002b;</sup></italic>/<italic>Fas<sup>lpr</sup></italic> mice in order to study the effect of a disrupted Fas-mediated apoptotic machinery on tumor development and progression. The results are summarized herein.</p></sec><sec sec-type="materials|methods" id="s2"><title>Material and Methods</title><sec id="s2a"><title>Mice and Tissue Processing</title><p>The animal protocols used in this study were approved by the University of Notre Dame Institutional Animal Care and Use Committee. Male <italic>Apc<sup>Min/&#x0002b;</sup></italic> and Fas-deficient (<italic>Fas<sup>lpr</sup></italic>) mice (5 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME). All animals were fed a rodent chow diet. For these studies, <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice were crossed with <italic>Fas<sup>lpr</sup></italic> mice to generate <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr/&#x0002b;</sup></italic> mice, which were then bred to generate <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice. Male <italic>Apc<sup>Min/&#x0002b;</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (8, 12, 16, 20, and 30 weeks) in a C57BL/6 background, were used for all analyses. Tumor counting was performed under a dissecting microscope by investigators blinded to the genotype. Intestines were opened longitudinally, cleaned, Swiss-rolled, fixed with periodate-lysine-paraformaldehyde (PLP), and embedded in paraffin.</p></sec><sec id="s2b"><title>Blood Analysis</title><p>Blood extracted intravenously from individual mice was treated with EDTA and an aliquot (50 &#x000b5;l) was applied to an automated CBC analyzer (Hemavet HV950FS, Drew Scientific, Oxford, CT, USA) in order to determine the number of leukocytes (lymphocytes, neutrophils, monocytes), erythrocytes (red blood cells, hemoglobin and hematocrit), and thrombocytes (platelets).</p></sec><sec id="s2c"><title>Histochemistry and Immunohistochemistry</title><p>Serial sections of paraffin-embedded tissue were cut for haematoxylin and eosin (H&#x00026;E) staining and for immunostaining. Active caspase-3 and Fas-L were identified utilizing polyclonal rabbit-anti-human active caspase-3 and Fas-L antibodies (Abcam, Cambridge, MA), followed by HRP-conjugated goat-anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA). PCNA was identified utilizing a monoclonal mouse-anti-human PCNA antibody (BioGenex, San Ramon, CA) as the primary antibody, followed by HRP-conjugated rabbit-anti-mouse IgG (Santa Cruz Biotechnology). A mouse monoclonal-anti-mouse p53 antibody (Abcam) was used to detect p53, followed by HRP-conjugated rabbit-anti-mouse IgG (AbD Serotec, Oxford, UK). Total Akt and phosphorylated Akt were identified utilizing polyclonal rabbit-anti-mouse Akt and pAkt antibodies (Abcam and Cell Signaling, Danvers, MA, respectively), followed by biotinylated swine-anti-rabbit IgG (Dako, Carpinteria, CA) and HRP-conjugated streptavidin (BioGenex). CD45 and Mac-3 were identified utilizing a monoclonal rat-anti-mouse antibodies for CD45 and Mac-3 (Pharmingen, San Diego, CA), followed by a biotinylated rabbit-anti-mouse IgG (Dako, Carpinteria, CA) and HRP conjugated streptavidin (Jackson, West Grove, PA). Phosphorylated Foxo3a was identified utilizing a polyclonal rabbit-anti-rat Foxo3a (phosphor S253) antibody (Abcam), followed by HRP-conjugated goat-anti-rabbit IgG (Santa Cruz Biotechnology). All stains were then developed in 3, 3&#x02032;-diaminobenzidine (DAB) and a haematoxylin QS counterstain was applied (Vector Laboratories, Burlington, CA).</p></sec><sec id="s2d"><title>Stain Quantification and Statistical Analysis</title><p>Immunohistochemical stains were quantified using Spectrum Plus (Version 9.0.748.1518) and ImageScope software (Aperio Technologies, Vista, CA). Slides were scanned and loaded into an electronic database at 20X by ScanScope CS (Aperio Technologies). For each stain, algorithms were developed to analyze either the percent positive stained area per tumor area (Fas-L, Akt and pAkt) or the number of positive cells per tumor area (PCNA, caspase-3, p53, CD45, Mac-3 and p-Foxo3a).</p><p>Scanned slides were viewed in ImageScope where regions were drawn around each tumor and analyzed with Spectrum software, using algorithms designed for each stain. Stains using percent positive area were analyzed using color deconvolution algorithms. Stains requiring the number of positive cells per tumor area were analyzed using algorithms that separate color by optical density and also separate cells by outer membrane size and roundness. Cells that fit within the parameters set for desired cell size and shape and stain were counted, as was the area of each tumor region. The average number of cells per tumor area was then determined.</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>For survival studies, the data were analyzed using the Kaplan-Meier treatment and the comparison of survival between both genotypes was performed using the log-rank test with Prism 4 software (GraphPad Software, La Jolla, CA). The Student's t-test was used for comparison of single pairs.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Fas Deletion in <italic>Apc<sup>Min/&#x0002b;</sup></italic> Mice Increases the Size and Number of Intestinal Adenomas</title><p>Based on preliminary transcriptional profiling results of human colon cancer samples, where a strong downregulation of a FAS-related receptor was observed (data not shown), along with published reports of compromised Fas-mediated apoptosis in colon cancer, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice were generated to determine the effects of a Fas deficiency in the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model. Intestines harvested at various timepoints revealed that <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice developed dramatically more intestinal adenomas than <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice, increasing rapidly with time (p&#x0003c;0.00001 at 8 weeks, p&#x0200a;&#x0003d;&#x0200a;0.0072 at 12 weeks, p&#x0200a;&#x0003d;&#x0200a;0.0012 at 16 weeks, p&#x0200a;&#x0003d;&#x0200a;0.00019 at 20 weeks and p&#x0003c;0.00001 at 30 wks, n&#x0200a;&#x0003d;&#x0200a;4&#x02013;10 for <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and 5&#x02013;21 for <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic>), and reaching a plateau of slightly more than 70 adenomas after 16 weeks of age (<xref ref-type="fig" rid="pone-0009070-g001">Fig. 1A</xref>). The largest difference was observed at 20 weeks, where <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice had on average 87 intestinal adenomas per mouse compared to 13 in the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice. The <italic>Fas<sup>lpr</sup></italic> mice, alone, did not generate any intestinal polyps. For most time points, <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice had slightly larger adenomas, reaching significance at 16 weeks (p&#x0003c;0.05) (<xref ref-type="fig" rid="pone-0009070-g001">Fig. 1B</xref>). At 30 weeks however, adenomas from <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice were significantly larger than adenomas from <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (p&#x0003c;0.01). Unlike <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice, where the location of adenomas is almost exclusively in the small intestine, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice after 16 weeks presented with large adenomas in the large intestine, additional to the ones located at the small intestine. Although there was significant tumor burden in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice, it was much lower than in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice. Additionally, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice had a significantly reduced survival rate relative to <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (<xref ref-type="fig" rid="pone-0009070-g001">Fig. 1C</xref>). The survival curves were compared using a log-rank test showing a significantly lower survival (p&#x0003c;0.001) in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;35) compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice (<italic>n&#x0200a;&#x0003d;&#x0200a;</italic>89). The percent survival of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice strongly decreased between 25 and 30 weeks and reached 44&#x00025; at 30 weeks. This is about 12 weeks earlier than that observed in <italic>Fas<sup>lpr</sup></italic> mice <xref ref-type="bibr" rid="pone.0009070-Wofsy1">&#x0005b;24&#x0005d;</xref>. Furthermore, unlike <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice presented with invasive lesions in all animals at 30 weeks (<xref ref-type="fig" rid="pone-0009070-g002">Fig. 2</xref>). The invasive lesions are not to be confused with herniation, a common occurrence in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice. All specimens were analyzed by a veterinary pathologist utilizing standardized guidelines <xref ref-type="bibr" rid="pone.0009070-Boivin1">&#x0005b;25&#x0005d;</xref>. The percentage of invasive lesions ranged from 3.0 to 15.4&#x00025; (<xref ref-type="table" rid="pone-0009070-t001">Table 1</xref>). However, metastasis to other organs was not detected.</p><fig id="pone-0009070-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g001</object-id><label>Figure 1</label><caption><title>Tumor burden and survival.</title><p>(<bold>A</bold>) Intestinal tumor number, (<bold>B</bold>) tumor size, and (<bold>C</bold>) survival rate of <italic>Apc<sup>Min/&#x0002b;</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice. Error bars in panels (<bold>A</bold>) and (<bold>B</bold>) represent standard error of the mean.</p></caption><graphic xlink:href="pone.0009070.g001"/></fig><fig id="pone-0009070-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g002</object-id><label>Figure 2</label><caption><title>Invasive lesions.</title><p>H&#x00026;E stains of intestinal adenoma sections of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice at 30 weeks. The panel on the top represents an entire polyp with evidence of an invasive lesion, further magnified in the lower panel. Invasive lesions were analyzed by a veterinary pathologist and were not identified as areas of herniation, which is common in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice.</p></caption><graphic xlink:href="pone.0009070.g002"/></fig><table-wrap id="pone-0009070-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.t001</object-id><label>Table 1</label><caption><title>Percentage of invasive lesions in 30 week <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice.</title></caption><alternatives><graphic id="pone-0009070-t001-1" xlink:href="pone.0009070.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">Invasive lesions</td><td align="left" rowspan="1" colspan="1">Non-invasive lesions</td><td align="left" rowspan="1" colspan="1">Percentage of invasive lesions</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AP266</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">3.00&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">AP281</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">8.70&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">AP285</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">7.10&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">AP286</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">7.90&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">AP287</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">15.40&#x00025;</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3b"><title>Adenomas from <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> Mice Show Increased Proliferation</title><p>To determine if increased polyps in the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice were due to an increase in cellular proliferation and/or a decrease in apoptosis, cells positive for proliferating cell nuclear antigen (PCNA) (<xref ref-type="fig" rid="pone-0009070-g003">Fig. 3</xref>) and caspase-3 (data not shown) were determined by immunohistochemistry. Several (18&#x02013;205) polyps from at least 4 mice were used for each time point and genotype. <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice had significantly more PCNA&#x0002b; cells per tumor area than <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice at most time points (p&#x0200a;&#x0003d;&#x0200a;0.0014 at 8 weeks, p&#x0200a;&#x0003d;&#x0200a;0.0038 at 16 weeks, p&#x0003c;0.0001 at 20 weeks and 30 weeks, n&#x0200a;&#x0003d;&#x0200a;24&#x02013;205 tumors for <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and 18&#x02013;58 tumors for <italic>Apc<sup>Min/&#x0002b;</sup></italic> in 4&#x02013;5 mice per genotype) (<xref ref-type="fig" rid="pone-0009070-g003">Fig. 3</xref>). Apoptosis activity was determined by measuring cleaved caspase-3 levels. Surprisingly, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> did not show a significant change in caspase-3&#x0002b; cells per tumor area at any time point, when compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice. As another marker of apoptosis, p53 was also measured by immunohistochemistry. An increase in p53 levels was observed in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice (<xref ref-type="fig" rid="pone-0009070-g004">Fig. 4</xref>). The p53 increase was observed at early time points; 8 weeks (p&#x0200a;&#x0003d;&#x0200a;0.0009), 12weeks (p&#x0200a;&#x0003d;&#x0200a;0.012), and 16 weeks (p&#x0003c;0.0001) in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (n&#x0200a;&#x0003d;&#x0200a;26&#x02013;177 tumors for <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and 18&#x02013;78 tumors for <italic>Apc<sup>Min/&#x0002b;</sup></italic> in 4&#x02013;5 mice per genotype). After 20 weeks, both genotypes had similar levels of p53.</p><fig id="pone-0009070-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g003</object-id><label>Figure 3</label><caption><title>Immunohistochemistry for PCNA in adenomas from <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup> and <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup><italic>/Fas<sup>lpr</sup></italic> mice.</title><p>(<bold>A</bold>) PCNA immunostains comparing <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> to <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice at 8 and 20 weeks. (<bold>B</bold>) Quantitation of PCNA positive cells per tumor area at five different time points. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="pone.0009070.g003"/></fig><fig id="pone-0009070-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g004</object-id><label>Figure 4</label><caption><title>Immunohistochemistry for p53 in adenomas from <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup> and <bold><italic>Apc<sup>Min/</sup></italic></bold><sup>&#x0002b;</sup><italic>/Fas<sup>lpr</sup></italic> mice.</title><p>(<bold>A</bold>) Immunostains for the apoptosis marker p53 in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice and <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice at 8 and 20 weeks. (<bold>B</bold>) Quantitation of p53 positive cells per tumor area at five different time points. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="pone.0009070.g004"/></fig></sec><sec id="s3c"><title>Fas-L Is Decreased in <italic>Apc<sup>Min/&#x0002b;</sup></italic> Mice Lacking Fas</title><p>Another study has reported an increase in intestinal tumorigenesis once functional Fas-L is lost in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice <xref ref-type="bibr" rid="pone.0009070-Fingleton1">&#x0005b;17&#x0005d;</xref>. To determine if, in our Fas-deficient model, the levels of Fas-L within the adenomas were altered, immunostains of Fas-L were performed on intestinal sections of <italic>Apc<sup>Min/&#x0002b;</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (<xref ref-type="fig" rid="pone-0009070-g005">Fig. 5</xref>). Adenomas from the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice had significantly less Fas-L per tumor area than <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice. This observation was consistent for all time points (p&#x0200a;&#x0003d;&#x0200a;0.039 at 8 weeks, p&#x0003c;0.0001 at 12, 16, 20 and 30 weeks, n&#x0200a;&#x0003d;&#x0200a;28&#x02013;198 tumors for <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and 17&#x02013;93 tumors for <italic>Apc<sup>Min/&#x0002b;</sup></italic> in 4&#x02013;5 mice per genotype).</p><fig id="pone-0009070-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g005</object-id><label>Figure 5</label><caption><title>Immunohistochemistry for Fas-L in adenomas from <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup> and <bold><italic>Apc<sup>Min/</sup></italic></bold><sup>&#x0002b;</sup><italic>/Fas<sup>lpr</sup></italic> mice.</title><p>(<bold>A</bold>) Immunostains for Fas-L comparing <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice at 8 and 20 weeks. (<bold>B</bold>) Quantitation of Fas-L immunostains. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="pone.0009070.g005"/></fig></sec><sec id="s3d"><title>Akt, Foxo3a, and Inflammatory Markers in Intestinal Tumors from <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup></italic> Mice</title><p>Fas-L, aside from triggering Fas dependent apoptosis, is considered to be an inducer of inflammation. To analyze inflammation within tumors, stains for CD45 and Mac-3 were performed on the intestines of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (<xref ref-type="fig" rid="pone-0009070-g006">Fig. 6A</xref>). At 30 weeks, there were fewer positive cells for CD45 in tumors of <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (617&#x000b1;99 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;17 in 4 mice) than in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (2006&#x000b1;86 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;133 in 5 mice) (p&#x0003c;0.0001) (<xref ref-type="fig" rid="pone-0009070-g006">Fig. 6B</xref>). Mac-3, an antigen present on macrophages, had the same trend with lower levels in tumors of <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (623&#x000b1;166 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;21 in 4 mice) than in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (5804&#x000b1;175 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;151 in 5 mice) (p&#x0003c;0.0001).</p><fig id="pone-0009070-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g006</object-id><label>Figure 6</label><caption><title>Inflammation in adenomas of <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup> and <italic>Apc</italic><sup>Min/&#x0002b;</sup><italic>/Fas<sup>lpr</sup></italic> mice.</title><p>(<bold>A</bold>) Immunostains for Mac-3, CD45, p-Foxo3a, Akt and pAkt in adenomas from <italic>Apc<sup>Min/&#x0002b;</sup></italic> and <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice at 30 weeks. (<bold>B</bold>) Quantitation of Mac-3, CD45, p-Foxo3a, Akt, and pAkt immunostains. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="pone.0009070.g006"/></fig><p>In addition to PCNA, cell survival was further analyzed by staining for total Akt and its activated phosphorylated form (p-Akt) (<xref ref-type="fig" rid="pone-0009070-g006">Fig. 6A</xref>). The stains revealed a predictable trend in which tumors from <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice showed higher levels of Akt (63.8&#x00025;&#x000b1;7.6 n&#x0200a;&#x0003d;&#x0200a;199 in 5 mice, versus 40.6&#x00025;&#x000b1;4.1, n&#x0200a;&#x0003d;&#x0200a;21 in 4 mice) and pAkt (53.0&#x00025;&#x000b1;10.8, n&#x0200a;&#x0003d;&#x0200a;186 in 5 mice, versus 13.7&#x00025;&#x000b1;2.0, n&#x0200a;&#x0003d;&#x0200a;28 in 5 mice) than <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (p&#x0003c;0.0001) (<xref ref-type="fig" rid="pone-0009070-g006">Fig. 6B</xref>). Akt is reported to decrease expression of Fas-L by phosphorylating and, therefore, inhibiting Foxo3a, a member of the forkhead family of transcription factors responsible for Fas-L expression <xref ref-type="bibr" rid="pone.0009070-Brunet1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Suhara1">&#x0005b;27&#x0005d;</xref>. In accordance with those reports, levels of phosphorylated Foxo3a (p-Foxo3a) were higher in the tumors of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice (7038&#x000b1;230 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;139 in 4 mice) compared to the tumors in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice (5523&#x000b1;398 &#x0002b;cells/mm<sup>2</sup>, n&#x0200a;&#x0003d;&#x0200a;20 in 3 mice) (p&#x0200a;&#x0003d;&#x0200a;0.017) (<xref ref-type="fig" rid="pone-0009070-g006">Fig. 6A,B</xref>).</p></sec><sec id="s3e"><title>Hematology Profile</title><p>Prior to perfusion, blood was collected from all animals for hematological profiling. Measurements of leukocyte (neutrophils, lymphocytes, and monocytes) levels revealed that the averages remained within the normal ranges (data not shown).</p><p><italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice, at most time points, were anemic as determined by red blood cell counts, hemoglobin, and percent hematocrit. However, <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice, as well as <italic>Fas<sup>lpr</sup></italic> mice were also anemic. Platelets, in all cases, were within normal ranges (data not shown).</p></sec></sec><sec id="s4"><title>Discussion</title><p>This study demonstrated that <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice develop more intestinal adenomas when Fas is absent. An increase in proliferation (measured by PCNA) was evident, especially at later time points where an increase in Akt and pAkt was also observed. Additionally, there was a decrease in Fas-L in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice. A significant increase in inflammation and Mac-3 was also observed in tumors of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice.</p><p>In the present study it was observed that at all time points (8, 12, 16, 20 and 30 weeks), <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice developed substantially more intestinal adenomas when Fas was eliminated. These adenomas also proved to be more aggressive. Incidences of intestinal prolapse were common in the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice, especially at the later time points. Overall, the poor health of these animals was evidenced by their diminished survival rate as they approached 30 weeks of age. These findings were not surprising and were in accord with expectations from disruption of the apoptotic pathway <xref ref-type="bibr" rid="pone.0009070-Bedi1">&#x0005b;28&#x0005d;</xref>. However, the levels of the apoptotic markers, activated caspase-3 and p53, were unexpected. There were no differences in activated caspase-3 levels, but an increase in p53 levels was observed in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice. Changes in cleaved caspase-3 were also absent in previous studies using <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice lacking Fas-L <xref ref-type="bibr" rid="pone.0009070-Fingleton1">&#x0005b;17&#x0005d;</xref>. On the other hand, p53, also an apoptotic marker, was higher in tumors of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice at early time points. However, this difference was attenuated at 30 weeks, when Akt and pAkt were observed to be higher in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice compared to <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice. Akt is a protein kinase activated by a variety of growth factors <xref ref-type="bibr" rid="pone.0009070-Burgering1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Franke1">&#x0005b;30&#x0005d;</xref> that in turn triggers activation of several cancer-relevant downstream effector molecules, resulting in an environment that promotes proliferation and cell survival <xref ref-type="bibr" rid="pone.0009070-Altomare1">&#x0005b;31&#x0005d;</xref>. It has previously been reported that Akt is capable of downregulating p53 through phosphorylation of Mdm2 that results in a translocation to the nucleus <xref ref-type="bibr" rid="pone.0009070-Mayo1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Zhou1">&#x0005b;33&#x0005d;</xref>. The increase of p53 might also be a compensatory mechanism for a lack of Fas pathway. The interdependence between Fas and p53 pathways has been demonstrated by others <xref ref-type="bibr" rid="pone.0009070-Fuchs1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-OConnor1">&#x0005b;35&#x0005d;</xref>.</p><p>In accordance with reports indicating that Akt regulation in Fas-L expression is due to phosphorylation and, therefore, cytoplasmic retention of the forkhead transcription factor FKHRL1/Foxo3a <xref ref-type="bibr" rid="pone.0009070-Brunet1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Suhara1">&#x0005b;27&#x0005d;</xref>, intestinal adenomas of the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice at later time points presented with fewer Fas-L than tumors found in the <italic>Apc<sup>Min/&#x0002b;</sup></italic>mice. This observation indicates that in the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model, a Fas deficiency does not compromise tumor growth. On the contrary, by disrupting the Fas machinery, these tumors developed faster, and in greater numbers. These results are consistent with previous reports highlighting the anti-tumor effects of Fas-L <xref ref-type="bibr" rid="pone.0009070-Arai1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Seino1">&#x0005b;36&#x0005d;</xref>, as well as with recent findings of increased tumor burden in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice deficient for Fas-L <xref ref-type="bibr" rid="pone.0009070-Fingleton1">&#x0005b;17&#x0005d;</xref>. However, there are a number of studies that report opposite findings where Fas-L confers more rapid tumor formation in murine melanoma cells <xref ref-type="bibr" rid="pone.0009070-Hahne1">&#x0005b;37&#x0005d;</xref>. Higher Fas-L expression has also been reported in liver metastasis of colon cancer compared to the primary tumor <xref ref-type="bibr" rid="pone.0009070-Mann1">&#x0005b;38&#x0005d;</xref>. Those findings might represent a compensatory mechanism for a disrupted Fas-mediated apoptotic pathway. Despite the general assumption that high levels of Fas-L would induce inflammation within the tumors, in the present study it was observed that <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice, which had far lower levels of Fas-L than <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice, showed an increase in inflammation at 30 weeks of age. The mechanism behind the increased level of inflammation in tumors of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice is likely related to a balance between membrane Fas-L (mFas-L) and soluble Fas-L (sFas-L) (<xref ref-type="fig" rid="pone-0009070-g007">Fig. 7</xref>). mFas-L is a well known inducer of inflammation while sFas-L has the opposite effect <xref ref-type="bibr" rid="pone.0009070-Hohlbaum1">&#x0005b;39&#x0005d;</xref>. Mmp7 is capable of cleaving mFas-L to yield sFas-L <xref ref-type="bibr" rid="pone.0009070-Powell1">&#x0005b;40&#x0005d;</xref>. The <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model and colon cancer in general show elevated levels of matrilysin <xref ref-type="bibr" rid="pone.0009070-GuillenAhlers1">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Kita1">&#x0005b;42&#x0005d;</xref>. Therefore, it is not unlikely to assume that in this context the balance between mFas-L and sFas-L would favor its soluble form and therefore a direct correlation between Fas-L and inflammation levels would be expected, as was observed in the present study. Fas-L expression is regulated by Foxo3a, a member of the forkhead family of transcription factors. Akt has been reported to decrease Fas-L expression by phosphorylation and therefore inactivation of Foxo3a. In accord with this mechanism, <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice showed higher levels of Akt, p-Akt, and p-Foxo3a, and lower levels of Fas-L.</p><fig id="pone-0009070-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009070.g007</object-id><label>Figure 7</label><caption><title>Proposed model for the increase in tumor burden in absence of Fas/CD95 in <italic>Apc<sup>Min/</sup></italic><sup>&#x0002b;</sup> mice.</title><p>p-Akt inactivates Foxo3a by phosphorylation and p-Foxo3a is not able to translocate to the nucleus. Foxo3a is involved in the transcription of Fas-L. Fas-L forms a homotrimer transmembrane complex with a cleavage site (black circles), that is recognized by Mmp7. Mmp7 cleavage of mFas-L yields sFas-L (grey rectangles). The membrane and soluble forms of Fas-L have opposite effects on inflammation.</p></caption><graphic xlink:href="pone.0009070.g007"/></fig><p>A relationship between inflammation and cancer has been identified in a number of studies, and it is widely accepted that inflammation creates conditions that promote tumor development (reviewed in <xref ref-type="bibr" rid="pone.0009070-Coussens1">&#x0005b;43&#x0005d;</xref>). Furthermore, Mac-3, an antigen present on macrophages, was present at higher levels in tumors of <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice and their presence within tumors promoted tumor growth, invasion, and metastasis <xref ref-type="bibr" rid="pone.0009070-Green1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Pollard1">&#x0005b;45&#x0005d;</xref>.</p><p>The results of the present study correlate to those of Fingleton <italic>et al.</italic><xref ref-type="bibr" rid="pone.0009070-Fingleton1">&#x0005b;17&#x0005d;</xref> with differences that are worthy of further consideration. Fingleton <italic>et al.</italic> used 17 week <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice lacking Fas-L instead of its receptor, Fas. Both studies detected high levels of Fas-L in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice. While deficiencies of either Fas or FasL resulted in an increase in tumor burden, in the current study, the increases in tumor number ranged from &#x0223c;300&#x00025;, at early time points, to over 500&#x00025;, at 16 weeks, whereas Fingleton <italic>et al.</italic> observed an increase nearly 100&#x00025; at 17 weeks. These differences in tumor burden are most likely associated with difference in the inflammatory response observed in these studies. Fingleton <italic>et al.</italic> did not observe any significant changes in macrophage or lymphocyte infiltration, but did see a 3-fold decrease in neutrophils in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice lacking Fas-L. In contrast, the current study demonstrated an obvious increase in the inflammatory response in <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice. This supports the premise that the role played by in inflammation is more relevant in tumor development than it is in tumor evasion of the immune system. The current study, however, suggests that in intestinal adenomas, the balance between mFas-L and sFas-L levels, resulting from Mmp7 proteolysis, may regulate the pro- or anti-inflammatory properties of Fas-L.</p><p>Among the main objectives for generating the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice was to determine if a more aggressive variant of the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model would evolve. At 30 weeks of age, all of the <italic>Apc<sup>Min/&#x0002b;</sup>/Fas<sup>lpr</sup></italic> mice had invasive lesions, which was not observed in the <italic>Apc<sup>Min/&#x0002b;</sup></italic> mouse model. It is likely that invasive lesions arise, at least in part, as a result of an increase in Akt and its active form, since this kinase has been shown to be involved in tumor invasion and metastasis <xref ref-type="bibr" rid="pone.0009070-Thant1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Bjornsti1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009070-Luo1">&#x0005b;48&#x0005d;</xref>.</p><p>In summary, this study demonstrated that an additional Fas deficiency in <italic>Apc<sup>Min/&#x0002b;</sup></italic> mice causes a dramatic increase in the number of intestinal tumors. The increase in the incidence of adenoma development and the invasiveness of these adenomas, paralleling a decrease in Fas-L in these mice, does not support the Fas counterattack notion in this model. The increase in Mac-3 and CD45 suggests a tumor permissive environment caused by a Fas-L modulated inflammation.</p></sec></body><back><ack><p>The authors thank Ms. Heather Tipton for assistance with imaging and Sarah Chapman and Mayra Sandoval-Cooper for assistance with histology.</p></ack><ref-list><title>References</title><ref id="pone.0009070-Ashkenazi1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year>1999</year><article-title>Apoptosis control by death and decoy receptors.</article-title><source>Curr Opin Cell Biol</source><volume>11</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">10209153</pub-id></mixed-citation></ref><ref id="pone.0009070-Lee1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Benveniste</surname><given-names>EN</given-names></name></person-group><year>2000</year><article-title>Differential regulation and function of Fas expression on glial cells.</article-title><source>J Immunol</source><volume>164</volume><fpage>1277</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">10640741</pub-id></mixed-citation></ref><ref id="pone.0009070-Itoh1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Yonehara</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>A</given-names></name><name><surname>Yonehara</surname><given-names>M</given-names></name><name><surname>Mizushima</surname><given-names>S</given-names></name><etal/></person-group><year>1991</year><article-title>The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.</article-title><source>Cell</source><volume>66</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">1713127</pub-id></mixed-citation></ref><ref id="pone.0009070-Suda1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suda</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Golstein</surname><given-names>P</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name></person-group><year>1993</year><article-title>Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.</article-title><source>Cell</source><volume>75</volume><fpage>1169</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">7505205</pub-id></mixed-citation></ref><ref id="pone.0009070-Danial1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danial</surname><given-names>NN</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group><year>2004</year><article-title>Cell death: critical control points.</article-title><source>Cell</source><volume>116</volume><fpage>205</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">14744432</pub-id></mixed-citation></ref><ref id="pone.0009070-Yao1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hamar</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.</article-title><source>Br J Cancer</source><volume>91</volume><fpage>1718</fpage><lpage>1725</lpage><pub-id pub-id-type="pmid">15494722</pub-id></mixed-citation></ref><ref id="pone.0009070-Mahidhara1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahidhara</surname><given-names>RS</given-names></name><name><surname>Queiroz De Oliveira</surname><given-names>PE</given-names></name><name><surname>Kohout</surname><given-names>J</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.</article-title><source>J Surg Res</source><volume>123</volume><fpage>302</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">15680394</pub-id></mixed-citation></ref><ref id="pone.0009070-Pitti1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitti</surname><given-names>RM</given-names></name><name><surname>Marsters</surname><given-names>SA</given-names></name><name><surname>Lawrence</surname><given-names>DA</given-names></name><name><surname>Roy</surname><given-names>M</given-names></name><name><surname>Kischkel</surname><given-names>FC</given-names></name><etal/></person-group><year>1998</year><article-title>Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.</article-title><source>Nature</source><volume>396</volume><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">9872321</pub-id></mixed-citation></ref><ref id="pone.0009070-OConnell1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>MW</given-names></name><name><surname>O'Sullivan</surname><given-names>GC</given-names></name><name><surname>Roche</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><etal/></person-group><year>1998</year><article-title>Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.</article-title><source>J Pathol</source><volume>186</volume><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">10211111</pub-id></mixed-citation></ref><ref id="pone.0009070-OConnell2"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>MW</given-names></name><name><surname>Nally</surname><given-names>K</given-names></name><name><surname>Houston</surname><given-names>A</given-names></name><name><surname>O'Sullivan</surname><given-names>GC</given-names></name><etal/></person-group><year>2000</year><article-title>Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.</article-title><source>Ann N Y Acad Sci</source><volume>910</volume><fpage>178</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">10911913</pub-id></mixed-citation></ref><ref id="pone.0009070-Vaux1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaux</surname><given-names>DL</given-names></name></person-group><year>1995</year><article-title>Immunology. Ways around rejection.</article-title><source>Nature</source><volume>377</volume><fpage>576</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">7566165</pub-id></mixed-citation></ref><ref id="pone.0009070-Yagita1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Seino</surname><given-names>K</given-names></name><name><surname>Kayagaki</surname><given-names>N</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name></person-group><year>1996</year><article-title>CD95 ligand in graft rejection.</article-title><source>Nature</source><volume>379</volume><fpage>682</fpage><pub-id pub-id-type="pmid">8602212</pub-id></mixed-citation></ref><ref id="pone.0009070-Restifo1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year>2000</year><article-title>Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.</article-title><source>Nat Med</source><volume>6</volume><fpage>493</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">10802692</pub-id></mixed-citation></ref><ref id="pone.0009070-Arai1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Nabel</surname><given-names>EG</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><year>1997</year><article-title>Gene transfer of Fas ligand induces tumor regression in vivo.</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><fpage>13862</fpage><lpage>13867</lpage><pub-id pub-id-type="pmid">9391118</pub-id></mixed-citation></ref><ref id="pone.0009070-Chappell1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>DB</given-names></name><name><surname>Zaks</surname><given-names>TZ</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year>1999</year><article-title>Human melanoma cells do not express Fas (Apo-1/CD95) ligand.</article-title><source>Cancer Res</source><volume>59</volume><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9892185</pub-id></mixed-citation></ref><ref id="pone.0009070-Kang1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Ascher</surname><given-names>NL</given-names></name><name><surname>Stock</surname><given-names>PG</given-names></name></person-group><year>1998</year><article-title>Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection.</article-title><source>Transplant Proc</source><volume>30</volume><fpage>538</fpage><pub-id pub-id-type="pmid">9532168</pub-id></mixed-citation></ref><ref id="pone.0009070-Fingleton1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingleton</surname><given-names>B</given-names></name><name><surname>Carter</surname><given-names>KJ</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><year>2007</year><article-title>Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.</article-title><source>Cancer Res</source><volume>67</volume><fpage>4800</fpage><lpage>4806</lpage><pub-id pub-id-type="pmid">17510409</pub-id></mixed-citation></ref><ref id="pone.0009070-Su1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>LK</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Preisinger</surname><given-names>AC</given-names></name><name><surname>Moser</surname><given-names>AR</given-names></name><etal/></person-group><year>1992</year><article-title>Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.</article-title><source>Science</source><volume>256</volume><fpage>668</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">1350108</pub-id></mixed-citation></ref><ref id="pone.0009070-Moser1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>AR</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Dove</surname><given-names>WF</given-names></name></person-group><year>1990</year><article-title>A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse.</article-title><source>Science</source><volume>247</volume><fpage>322</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">2296722</pub-id></mixed-citation></ref><ref id="pone.0009070-Kinzler1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><year>1996</year><article-title>Lessons from hereditary colorectal cancer.</article-title><source>Cell</source><volume>87</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">8861899</pub-id></mixed-citation></ref><ref id="pone.0009070-Matloff1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matloff</surname><given-names>ET</given-names></name><name><surname>Brierley</surname><given-names>KL</given-names></name><name><surname>Chimera</surname><given-names>CM</given-names></name></person-group><year>2004</year><article-title>A clinician's guide to hereditary colon cancer.</article-title><source>Cancer J</source><volume>10</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">15530254</pub-id></mixed-citation></ref><ref id="pone.0009070-Reya1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year>2005</year><article-title>Wnt signalling in stem cells and cancer.</article-title><source>Nature</source><volume>434</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">15829953</pub-id></mixed-citation></ref><ref id="pone.0009070-Castellone1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellone</surname><given-names>MD</given-names></name><name><surname>Teramoto</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Druey</surname><given-names>KM</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name></person-group><year>2005</year><article-title>Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.</article-title><source>Science</source><volume>310</volume><fpage>1504</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">16293724</pub-id></mixed-citation></ref><ref id="pone.0009070-Wofsy1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wofsy</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>ED</given-names></name><name><surname>Roths</surname><given-names>JB</given-names></name><name><surname>Dauphinee</surname><given-names>MJ</given-names></name><name><surname>Kipper</surname><given-names>SB</given-names></name><etal/></person-group><year>1981</year><article-title>Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.</article-title><source>J Exp Med</source><volume>154</volume><fpage>1671</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">6975351</pub-id></mixed-citation></ref><ref id="pone.0009070-Boivin1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boivin</surname><given-names>GP</given-names></name><name><surname>Washington</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Pretlow</surname><given-names>TP</given-names></name><etal/></person-group><year>2003</year><article-title>Pathology of mouse models of intestinal cancer: consensus report and recommendations.</article-title><source>Gastroenterology</source><volume>124</volume><fpage>762</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">12612914</pub-id></mixed-citation></ref><ref id="pone.0009070-Brunet1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Bonni</surname><given-names>A</given-names></name><name><surname>Zigmond</surname><given-names>MJ</given-names></name><name><surname>Lin</surname><given-names>MZ</given-names></name><name><surname>Juo</surname><given-names>P</given-names></name><etal/></person-group><year>1999</year><article-title>Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.</article-title><source>Cell</source><volume>96</volume><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">10102273</pub-id></mixed-citation></ref><ref id="pone.0009070-Suhara1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhara</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>H-S</given-names></name><name><surname>Kirshenbaum</surname><given-names>LA</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name></person-group><year>2002</year><article-title>Suppression of Akt signaling induces Fas ligand expression: Involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation.</article-title><volume>22</volume><fpage>680</fpage><lpage>691</lpage></mixed-citation></ref><ref id="pone.0009070-Bedi1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedi</surname><given-names>A</given-names></name><name><surname>Pasricha</surname><given-names>PJ</given-names></name><name><surname>Akhtar</surname><given-names>AJ</given-names></name><name><surname>Barber</surname><given-names>JP</given-names></name><name><surname>Bedi</surname><given-names>GC</given-names></name><etal/></person-group><year>1995</year><article-title>Inhibition of apoptosis during development of colorectal cancer.</article-title><source>Cancer Res</source><volume>55</volume><fpage>1811</fpage><lpage>1816</lpage><pub-id pub-id-type="pmid">7728743</pub-id></mixed-citation></ref><ref id="pone.0009070-Burgering1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgering</surname><given-names>BM</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name></person-group><year>1995</year><article-title>Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.</article-title><source>Nature</source><volume>376</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">7637810</pub-id></mixed-citation></ref><ref id="pone.0009070-Franke1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>TF</given-names></name><name><surname>Yang</surname><given-names>S-I</given-names></name><name><surname>Chan</surname><given-names>TO</given-names></name><name><surname>Datta</surname><given-names>K</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name><etal/></person-group><year>1995</year><article-title>The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.</article-title><source>Cell</source><volume>81</volume><fpage>727</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">7774014</pub-id></mixed-citation></ref><ref id="pone.0009070-Altomare1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altomare</surname><given-names>DA</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name></person-group><article-title>Perturbations of the AKT signaling pathway in human cancer.</article-title><source>Perturbations of the AKT signaling pathway in human cancer</source><volume>24</volume><fpage>7455</fpage><lpage>7464</lpage></mixed-citation></ref><ref id="pone.0009070-Mayo1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayo</surname><given-names>LD</given-names></name><name><surname>Donner</surname><given-names>DB</given-names></name></person-group><year>2002</year><article-title>The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.</article-title><source>Trends Biochem Sci</source><volume>27</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">12217521</pub-id></mixed-citation></ref><ref id="pone.0009070-Zhou1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><year>2002</year><article-title>Novel targets of Akt, p21(Cipl/WAF1), and MDM2.</article-title><source>Semin Oncol</source><volume>29</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12138399</pub-id></mixed-citation></ref><ref id="pone.0009070-Fuchs1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>EJ</given-names></name><name><surname>McKenna</surname><given-names>KA</given-names></name><name><surname>Bedi</surname><given-names>A</given-names></name></person-group><year>1997</year><article-title>p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32{beta}.</article-title><source>Cancer Res</source><volume>57</volume><fpage>2550</fpage><lpage>2554</lpage><pub-id pub-id-type="pmid">9205051</pub-id></mixed-citation></ref><ref id="pone.0009070-OConnor1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types.</article-title><source>Cancer Res</source><volume>60</volume><fpage>1217</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">10728678</pub-id></mixed-citation></ref><ref id="pone.0009070-Seino1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seino</surname><given-names>K</given-names></name><name><surname>Kayagaki</surname><given-names>N</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name></person-group><year>1997</year><article-title>Antitumor effect of locally produced CD95 ligand.</article-title><source>Nat Med</source><volume>3</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">9018234</pub-id></mixed-citation></ref><ref id="pone.0009070-Hahne1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahne</surname><given-names>M</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Schroter</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Schreier</surname><given-names>M</given-names></name><etal/></person-group><year>1996</year><article-title>Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.</article-title><source>Science</source><volume>274</volume><fpage>1363</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">8910274</pub-id></mixed-citation></ref><ref id="pone.0009070-Mann1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>B</given-names></name><name><surname>Gratchev</surname><given-names>A</given-names></name><name><surname>Bohm</surname><given-names>C</given-names></name><name><surname>Hanski</surname><given-names>ML</given-names></name><name><surname>Foss</surname><given-names>HD</given-names></name><etal/></person-group><year>1999</year><article-title>FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas.</article-title><source>Br J Cancer</source><volume>79</volume><fpage>1262</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">10098769</pub-id></mixed-citation></ref><ref id="pone.0009070-Hohlbaum1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hohlbaum</surname><given-names>AM</given-names></name><name><surname>Moe</surname><given-names>S</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.</article-title><source>J Exp Med</source><volume>191</volume><fpage>1209</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">10748238</pub-id></mixed-citation></ref><ref id="pone.0009070-Powell1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>WC</given-names></name><name><surname>Fingleton</surname><given-names>B</given-names></name><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Boothby</surname><given-names>M</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><year>1999</year><article-title>The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.</article-title><source>Current Biology</source><volume>9</volume><fpage>1441</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">10607586</pub-id></mixed-citation></ref><ref id="pone.0009070-GuillenAhlers1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillen-Ahlers</surname><given-names>H</given-names></name><name><surname>Buechler</surname><given-names>SA</given-names></name><name><surname>Suckow</surname><given-names>MA</given-names></name><name><surname>Castellino</surname><given-names>FJ</given-names></name><name><surname>Ploplis</surname><given-names>VA</given-names></name></person-group><year>2008</year><article-title>Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/&#x0002b; mice.</article-title><source>Carcinogenesis</source><volume>29</volume><fpage>1421</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">18499699</pub-id></mixed-citation></ref><ref id="pone.0009070-Kita1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kita</surname><given-names>H</given-names></name><name><surname>Hikichi</surname><given-names>Y</given-names></name><name><surname>Hikami</surname><given-names>K</given-names></name><name><surname>Tsuneyama</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>ZG</given-names></name><etal/></person-group><year>2006</year><article-title>Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis.</article-title><source>J Gastroenterol</source><volume>41</volume><fpage>1053</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">17160516</pub-id></mixed-citation></ref><ref id="pone.0009070-Coussens1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><year>2002</year><article-title>Inflammation and cancer.</article-title><source>Nature</source><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id></mixed-citation></ref><ref id="pone.0009070-Green1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>CE</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Montel</surname><given-names>V</given-names></name><name><surname>Hsiao</surname><given-names>G</given-names></name><name><surname>Lester</surname><given-names>RD</given-names></name><etal/></person-group><year>2009</year><article-title>Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization.</article-title><source>PLoS ONE</source><volume>4</volume><fpage>e6713</fpage><pub-id pub-id-type="pmid">19696929</pub-id></mixed-citation></ref><ref id="pone.0009070-Pollard1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><year>2004</year><article-title>Tumour-educated macrophages promote tumour progression and metastasis.</article-title><source>Nat Rev Cancer</source><volume>4</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">14708027</pub-id></mixed-citation></ref><ref id="pone.0009070-Thant1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thant</surname><given-names>AA</given-names></name><name><surname>Nawa</surname><given-names>A</given-names></name><name><surname>Kikkawa</surname><given-names>F</given-names></name><name><surname>Ichigotani</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><year>2000</year><article-title>Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.</article-title><source>Clin Exp Metastasis</source><volume>18</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">11467775</pub-id></mixed-citation></ref><ref id="pone.0009070-Bjornsti1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornsti</surname><given-names>MA</given-names></name><name><surname>Houghton</surname><given-names>PJ</given-names></name></person-group><year>2004</year><article-title>Lost in translation: dysregulation of cap-dependent translation and cancer.</article-title><source>Cancer Cell</source><volume>5</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">15193254</pub-id></mixed-citation></ref><ref id="pone.0009070-Luo1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year>2003</year><article-title>Targeting the PI3K-Akt pathway in human cancer: rationale and promise.</article-title><source>Cancer Cell</source><volume>4</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">14585353</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by NIH (NHLBI) grant HL 73750 (FJC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>